Latest Pharma and Biotech News
Pharmaceutical
25 November 2024 In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards.
Today's issue
Refine Search
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Pharmaceutical
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Pharmaceutical
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
All news
Biotechnology
Danish allergy expert ALK Abello (ALKB: DC) has reported positive Phase III results from a trial of its sublingual allergy immunotherapy tablet for the treatment of allergic rhinitis in children. 9 June 2023
Biotechnology
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) yesterday voted unanimously 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in new-borns and infants born during or entering their first RSV season. 9 June 2023
Biotechnology
German radiopharmaceutical biotech ITM Isotope Technologies has announced an equity investment round of 255 million euros ($273 million) led by Temasek. 9 June 2023
Generics
Russian pharmaceutical companies will receive additional subsidies from the state for the development of analogues of foreign drugs, as part of the current state plans for the reduction of import dependence in the country’s pharmaceutical sector, The Pharma Letter’s local correspondent reports. 9 June 2023
Biotechnology
Privately-held US firms Aviko Radiopharmaceuticals and Neutron Therapeutics have announced the formation of a strategic partnership to advance boron neutron capture therapy (BNCT) to treat cancer. 8 June 2023
Generics
The Indian government is exploring the possibility of introducing a Production Linked Incentive (PLI) scheme for basic chemicals and active pharmaceutical ingredients (API) industries. 8 June 2023
Pharmaceutical
The number of medicines recalled by manufacturers due to defects has increased 153% in the UK since 2017, according to new figures from the Medicines and Healthcare products Regulatory Agency (MHRA), with relaxed regulations during Covid one possible factor behind the increase. 8 June 2023
Biotechnology
Californian biopharma FibroGen suffered a setback in part of its development of pamrevlumab, sending its shares 11% lower in Wednesday’s trading. 8 June 2023
Generics
Israeli generics giant Teva Pharmaceutical Industries said today that its US subsidiary has fully resolved its nationwide settlement agreement related to opioid claims. 8 June 2023
Biosimilars
South Korean contract development and manufacturing organization (CDMO) Samsung Biologics today revealed it has entered another strategic partnership with US pharma giant Pfizer (NYSE: PFE). 8 June 2023
Biotechnology
A series B financing round will swell the coffers of Massachusetts, USA-based biotech Upstream Bio to the tune of $200 million. 8 June 2023
Biotechnology
Ahead of a key meeting from the US Food and Drug Administration’s scientific advisory panel, briefing notes reveal a broadly positive view of Eisai and Biogen’s new Alzheimer’s med. 8 June 2023
Biotechnology
Legend Biotech and Janssen have announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) relating to their partnered asset Carvykti (ciltacabtagene autoleucel). 8 June 2023
Biotechnology
California, USA-based biotech start-up Bitterroot Bio has emerged from stealth with a $145 million Series A financing. 8 June 2023
Pharmaceutical
The European Commission has authorized Arexvy (respiratory syncytial virus vaccine, adjuvanted), developed by UK pharma major GSK, for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older. 8 June 2023
Biotechnology
The market for Alzheimer's disease (AD) drugs is projected to experience robust growth at a compound annual growth rate of 20.0% from $2.2 billion in 2020 to $13.7 billion in 2030 across the eight major markets (8MM: the USA, France, German, Spain, the UK, Japan and China). 8 June 2023
Biotechnology
Privately-held Dutch biotech Amarna Therapeutics has appointed Dr Henk Streefkerk as the company’s new chief executive and medical director. 7 June 2023
Biotechnology
Flagship Pioneering founded company Ring Therapeutics today announced the appointment of Konstantin Konstantinov as its chief technology officer. 7 June 2023
Biotechnology
Lynparza (olaparib) has been recommended by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have had two or more courses of platinum-based chemotherapy. 7 June 2023
Pharmaceutical
The US Food and Drug Administration (FDA) has announced the availability of a draft guidance with updated recommendations for good clinical practices (GCPs) aimed at modernizing the design and conduct of clinical trials. 7 June 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze